Skip to main content
padlock icon - secure page this page is secure

Recent Developments in the Synthesis of Antitumor-active Glycyrrhetinic Acid Derivatives

Buy Article:

$68.00 + tax (Refund Policy)

A serious flaw of many chemotherapeutics employed now for the (post-surgery) treatment of malignant tumors is their high cytotoxicity against vital organs. In addition, tumor cells that survive chemotherapy often show pronounced drug resistance against a wide range of therapeutics. Recently, glycyrrhetinic acid derivatives derived from a cheap and easy-to-obtain natural product have attracted pharmacological interest. Many derivatives of glycyrrhetinic acid showed good to excellent cytotoxicity and inhibited the proliferation of a wide range of human tumor cells. They act predominantly by apoptosis, thus making them an interesting and even fascinating starting point for the development of selective, effective and safe antitumor active drugs.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antitumor activity; apoptosis; glyccyrhizin; glycyrrhetinic acid

Document Type: Research Article

Publication date: August 1, 2014

More about this publication?
  • Mini-Reviews in Organic Chemistry publishes original reviews on all areas of organic chemistry including synthesis, bioorganic, medicinal, natural products, organometallic, supramolecular, molecular recognition, and physical organic chemistry. The emphasis will be on publishing quality papers very rapidly. Mini-reviews will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts.

    The journal is essential reading to all organic chemists in both academia and industry.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more